Key Points Company and Industry * Company: Xindashenwu * Industry: Biotechnology, pharmaceuticals Core Views and Arguments * Globalization Strategy: Xindashenwu aims to expand internationally with a focus on innovation as the cornerstone. This strategy is driven by the establishment of Forvita as a platform for overseas development. * Forvita: Forvita, a subsidiary of Xindashenwu, was established in 2021 and has been developing products in the United States and Europe. The company has faced challenges, including the suspension of certain projects and a decrease in share price. * Investment: Xindashenwu plans to invest in Forvita using its own funds to support its globalization efforts. This investment is aimed at solidifying the company's commitment to Forvita and addressing investor concerns. * Risk and Return: The biopharmaceutical industry is characterized by high risk and uncertainty. The success of Forvita's products is not guaranteed, and the valuation of the company may fluctuate accordingly. Other Important Content * Strategic Meetings: Xindashenwu holds annual strategy meetings to set long-term goals and KPIs. The 2021 strategic meeting focused on globalization and innovation. * Innovation Laboratory: Xindashenwu established a laboratory in Maryland to drive innovation and product development. * Clinical Development: Forvita has a clinical team with expertise in regulatory affairs and clinical research. * Investor Relations: Xindashenwu plans to continue providing updates on its financial performance and business developments. References * [doc id='1'] * [doc id='2'] * [doc id='3'] * [doc id='4'] * [doc id='5'] * [doc id='6'] * [doc id='7'] * [doc id='8'] * [doc id='9'] * [doc id='10'] * [doc id='11'] * [doc id='12'] * [doc id='13'] * [doc id='14'] * [doc id='15']
信达生物20241029